Placeholder Banner

BIO Statement on Senate Reintroduction of the PASTEUR Act

June 24, 2026

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act in the Senate:

“Moving the PASTEUR Act of 2026 forward marks meaningful progress in tackling one of our most serious public health crises. Antimicrobial resistance continues to grow every day and leaves patients fighting infections with dwindling treatment options. PASTEUR takes an important step toward restoring a sustainable antimicrobial ecosystem by promoting a model that encourages the development of innovative therapies against the most dangerous pathogens while ensuring they are used judiciously. We recognize and appreciate the bipartisan leadership behind this legislation to advance a policy solution that both fosters innovation and helps guarantee patients timely access to life-saving antimicrobial treatments.”

###

Discover More
WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Chief of Global Health of the Biotechnology Innovation Organization (BIO), released the following statement on the loss of the United States’ measles elimination status.“The loss of…
Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America’s health, prosperity, national security, and geopolitical strengthWASHINGTON (November 10, 2026) - The Biotechnology Innovation…
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…